A structured approach for identifying disease analogs

Payers will often look to disease analogs when making pricing and coverage decisions. These disease analogs can inform the level of rebates, need for prior authorization/utilization management, and the drug’s cost sharing tier. Traditionally, however, disease analogs are selected on an ad hoc basis. In a recent JMCP paper titled “A structured approach for identifying…

Read More

As Shared Decision-Making Ails, AI May Save This Human Interaction

By MICHAEL MILLENSON Shared decision-making between doctors and patients may be “the pinnacle of patient-centered care,” but three new medical journal articles suggest it’s encountering more problems than peaks. Yet counterintuitively, it may be artificial intelligence that rescues this intimately human interaction. “Shared decision-making is at a crossroads,” declares a Perspective in the Journal of General…

Read More